icon-folder.gif   Conference Reports for NATAP  
  62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back grey_arrow_rt.gif
Baseline Viral Voad Predicts SVR: Effect of Baseline Viral Load (VL) on Response of Boceprevir (BOC) Plus Peginterferon Alfa-2b/Ribavirin (PR) in Patients Infected With HCV Genotype 1
  Reported by jules Levin
AASLD Nov 5-9 2011 SF
S. C. Gordon,1 K. R. Reddy,2 J. McCone,3 I. M. Jacobson,4 R. Esteban,5 L. D. Pedicone,6 J. Shen,6 M. Burroughs,6 C. Brass,6 J. Albrecht,6 E. Lawitz7 1Henry Ford Hospital, Detroit, MI; 2University of Pennsylvania, Philadelphia, PA; 3Gastroenterology-Hepatology-Certified Endoscopy Centers, Alexandria, VA; 4Weill Cornell Medical College, New York, NY; 5Vall d'Hebron Hospital, Barcelona, Spain; 6Merck Sharp & Dohme Corp., Whitehouse Station, NJ;
· Compared with PR alone, PR + BOC benefited both treatment-naive patients and previous treatment failures, regardless of baseline VL
· In both treatment groups (PR alone and PR + BOC), patients with baseline VL ≤1 million IU/mL had higher SVR rates than patients with baseline VL >1 million IU/mL
· In previously untreated patients, baseline VL >10 million IU/mL was associated with a considerably higher relapse rate among patients who received PR alone
-Patients with baseline VL >10 million IU/mL who received BOC + PR had relapse rates similar to those in patients with baseline VL between 1 million and 10 million IU/mL









1. Poordad F, McCone J, Bacon BR, et al. N Engl J Med. 2011;364:1195-1206.
2. Bacon B, Gordon SC, Lawitz E, et al. N Engl J Med. 2011;364:1207-1217.